Overview
Seylan Bank is a full-service Sri Lankan commercial bank across retail, SME and corporate clients, with fee and transaction banking augmenting core lending. The most important change is operational: the June quarter delivered a record net margin and double-digit profit growth, while the stock still trades below book. The setup, as at 6 Aug 2026, is strong operating delivery against a still-cautious multiple, with NIM pressure the main watch item.
Price performance
Recent returns lag or track the market. The share fell 7.5% over three months versus the ASPI’s -6.5%, and is down 10.5% over six months versus -11.3% for the index. Over one year it is up 8.3% against the ASPI’s 9.3%.
Valuation
The voting line trades at P/E 4.89 versus the sector median 7.66 and P/B 0.72 versus 1.02, while offering a 4.1% dividend yield against the sector’s 3.4%. With FY2025 ROE at 14.5% and a 19.9% payout, the low P/B is broadly consistent with the low P/E, leaving room for re-rating if earnings momentum persists.
News and sentiment
Coverage is about normal, with 10 material articles in 90 days, 8 positive and 2 neutral. Press reports on 31 Jul confirm H1 2026 PAT of LKR 6.08 billion and note NIM eased to 4.16%. Strategic interest was evident as Rayynor Silva lifted his stake to 10% via a roughly LKR 1.2 billion purchase in May. A first and final dividend of LKR 4.00 per share went ex on 2 Apr 2026.
Financials
Q2 (to 30 Jun 2026) saw net profit rise 16.3% year-on-year to a quarterly high in the available series, with operating profit up and costs contained. Operating margin widened by 0.1 points to 48.6%, and net margin improved to 24.3% from 23.2% a year ago, a record for the quarterly series. Shares outstanding held flat across the period, so per-share gains reflect real profit growth. For FY2025, ROE was 14.5% on a 25.2% net margin with a conservative 19.9% payout, consistent with the bank’s capacity to fund balance-sheet growth.
Risks
Core spread pressure is visible, with H1 NIM at 4.16%. Credit costs nudged up in H1 per news, and any acceleration would bite earnings leverage. Regulatory scrutiny across the sector and AML compliance risks remain live, while the stock’s beta to the ASPI is elevated at 1.81, amplifying market swings.
Outlook
As at 6 Aug 2026, the next catalyst is the September-quarter filing, expected between 28 Oct 2026 and 28 Jan 2027. The read-through will be whether NIM stabilises and impairments remain contained; if they do, the combination of record margins and sub-book valuation could sustain, whereas a y/y net profit decline would challenge the re-rating case.